Startups
DARAPRIM® is used with other medication (such as a sulfonamide) to treat a serious parasite infection (toxoplasmosis) of the body, brain, or eye or to prevent toxoplasmosis infection in people with HIV infection.
Overview
Employees
11-50
Founded date
2016
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 22, 2022 | Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer | |
| Sep 13, 2019 | MRC’s first decade of translational research funding leads to £1.1bn private-sector investment and new therapies for patients | MRC’s first decade of translational research funding leads to £1.1bn private-sector investment and new therapies for patients 13-09-2019 A new report has found that MRC funding schemes for translational research have boosted the UK’s life s... |
| May 4, 2018 | For shame: ‘Pharma Bro’ Shkreli is in prison, but Daraprim’s price is still high | It was 2015 when Martin Shkreli, then CEO of Turing Pharmaceuticals and the notorious “pharma bro,” jacked up the cost of the lifesaving drug Daraprim by 5,000 percent. Overnight, its price tag skyrocketed from $13.50 a pi... |
| May 4, 2018 | Martin Shkreli’s in prison but Daraprim prices are still high | Shkreli, 35, is now serving a seven-year prison term for securities fraud (unrelated to Daraprim). Turing has renamed itself Vyera Pharmaceuticals. But Daraprim, which costs pennies to make and is used to treat the parasitic infection toxop... |
| Martin Shkreli’s in prison but Daraprim prices are still high | Lead defense attorney Benjamin Brafman walks with former pharmaceutical executive Martin Shkreli after the jury issued a verdict at the U.S. District Court for the Eastern District of New York, August 4, 2017 in the Brooklyn borough of New ... |
Reviews 0
FAQ about For Patients
When was For Patients founded?
For Patients was founded in 2016.
What has the press written about For Patients?
Parsers VC has collected 6 articles mentioning For Patients, among them “Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer” (Nov 22, 2022) and “MRC’s first decade of translational research funding leads to £1.1bn private-sector investment and new therapies for patients” (Sep 13, 2019).
Is For Patients still active?
Yes, For Patients is active; its latest activity on Parsers VC dates from Nov 3, 2026.